RARE News and Press, Ultragenyx Pharmaceutical Inc. From 10/27/22

NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ca...

Summary Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 mi...

Guggenheim has upgraded Ultragenyx Pharmaceutical ( NASDAQ: RARE ) to buy as the company is trading at a discount to its mid-cap biotech peers. The firm has a $50 price target (~30% upside based on Wednesday's close). Analyst Debjit Chattopadhyay said that the company'...

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) granted of non-qualified stock options to buy 13K common shares and 6.5K restricted stock units to one newly hired non-executive officer. The awards were granted under the Ultragenyx Employment Inducement Plan, the company sai...

Summary Due to its tremendous pressure, the 2021/2022 Biotech Bear market knocked out nearly all biotech innovators. Nevertheless, certain rare companies like Regenxbio are defying bear market expectations. Asides from the recent AbbVie mega partnership, Regenxbio's RGX314 is ...

NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare...

Summary Ultragenyx has built a remunerative, albeit not yet profitable, business around treating patients with orphan and ultra-orphan diseases. The problem from an investor's viewpoint is its outsized expense profile. Ultragenyx has an impressive pipeline and strong liquidity...

NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medica...

Evercore ISI has downgraded Ultragenyx Pharmaceuticals ( NASDAQ: RARE ) to in line from outperform citing uncertainty with the timing of a late-stage trial for the company's Angelman Syndrome candidate GTX-102. The firm cut its price target to $60 from $90 (~13% upside based...

Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.26 misses by $0.49 . Revenue of $89.34M (+2.7% Y/Y) beats by $2.01M . As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million Outlook: T...